ProCE Banner Activity

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Multidisciplinary Team

Slideset Download

Download this slideset from a live meeting series to learn about multidisciplinary approaches to managing high-risk, HR-positive/HER2-negative early breast cancer.

Released: January 04, 2023

Share

Faculty

Erika P. Hamilton

Erika P. Hamilton, MD

Director, Breast and Gynecologic Cancer Research Program
Drug Development Unit
Sarah Cannon Research Institute
Investigator
Tennessee Oncology
Nashville, Tennessee

Joyce O’Shaughnessy

Joyce O’Shaughnessy, MD

Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
US Oncology
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Lilly

Faculty Disclosure

Erika P. Hamilton, MD: consultant/advisor (paid to institution): Arcus, Arvinas, AstraZeneca, Daiichi Sankyo, Deciphera, Ellipses, Greenwich LifeSciences, iTeos, Janssen, Lilly, Loxo, Mersana, Novartis, Orum, Pfizer, Relay Therapeutics, Roche/Genentech, SeaGen, Verascity Science; researcher (paid to institution): AbbVie, Acerta Pharma, Accutar Biotechnology, ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, Black Diamond, Bliss BioPharmaceuticals, Boehringer Ingelheim, Cascadian Therapeutics, Clovis, Compugen, Cullen-Florentine, Curis, CytomX, Daiichi Sankyo, Dana-Farber Cancer Institute, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Ellipses, Elucida Oncology, EMD Serono, Fochon, FujiFilm, G1 Therapeutics, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity, InvestisBio, Jacobio, Karyopharm, Leap Therapeutics, Lilly, Lycera, Mabspace Biosciences, Macrogenics, MedImmune, Merck, Mersana, Merus, Millennium, Molecular Templates, Myriad Genetic Laboratories, Novartis, Nucana, Olema, OncoMed, Onconova Therapeutics, ORIC, Orinove, Pfizer, PharmaMar, Pieris, Pionyr Immunotherapeutics, Plexxikon, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, Roche/Genentech, SeaGen, Sermonix, Shattuck Labs, Silverback, StemCentRx, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque Therapeutics, Treadwell Therapeutics, Verastem, Vincerx Pharma, Zenith Epigenetics, Zymeworks.

Joyce O’Shaughnessy, MD: consultant/advisor/speaker: AbbVie, Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, Athenex, Bristol-Myers Squibb, Carrick Therapeutics, Celgene, Daiichi Sankyo, Eisai, G1 Therapeutics, Genentech, Genzyme, Gilead Sciences, GRAIL, Halozyme Therapeutics, Heron Therapeutics, Immunomedics, Ipsen Biopharmaceuticals, Lilly, Merck, Myriad, Necktar Therapeutics, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre, Prime Oncology, Puma Biotechnology, Roche, Samsung Bioepis, Sandoz, Sanofi, Seagen, Syndax, Synthon, Taiho Oncology, Takeda.